Literature DB >> 9360028

Influence of aspirin usage on blood pressure: dose and administration-time dependencies.

R C Hermida1, J R Fernández, D E Ayala, A Mojón, M Iglesias.   

Abstract

This study investigates the possible effects of acetylsalicylic acid (ASA; aspirin) on systolic (S) and diastolic (D) blood pressure (BP) in healthy and mildly hypertensive subjects receiving ASA at different times according to their rest-activity cycle. A double-blind, randomized, controlled trial was conducted in 73 healthy young adult volunteers and 18 previously untreated subjects with mild hypertension. The BP of each subject was automatically monitored every 30 minutes for 48h before the trial and at the end of a one-week course of placebo and a one-week course of ASA. Healthy volunteers were randomly assigned to one of six groups, defined according to the dose of ASA (either 500 mg/day, the usual commercial dose; or 100 mg/day) and timing of ASA and placebo (within 2h after awakening, Time 1; 7h to 9h after awakening, Time 2; or within 2h of bedtime, Time 3). Subjects with mild hypertension received the low dose of 100 mg/day ASA, as well as one week of placebo, and were randomly assigned to one of the same three groups defined above according to the time of treatment. A small (approximately 2 mmHg in the 24h mean of SBP), but statistically significant, BP reduction was found when 500 mg/day ASA was given to healthy volunteers at Time 2. With 100 mg/day, the effect of ASA in healthy subjects was comparable to the BP reduction found with the higher dose for Time 2; there was again no effect on BP at Time 1, but we found a statistically significant effect at Time 3 (2.3 mmHg reduction in the 24h mean of SBP), larger than for Time 2. For hypertensive patients, the BP reduction was again statistically significant for Time 2 and, to a greater extent, for Time 3 (approximately 4.5 mmHg for both SBP and DBP); all patients in these two groups showed a BP reduction after one week of ASA. The effect was about three times as large as the BP reduction obtained in healthy subjects treated with 100 mg/day ASA. Results indicate a statistically significant time- and dose-dependent effect of ASA on BP. In any meta-analysis of ASA effects, inquiries about the time when subjects took the drug are indicated and may account for discrepancies in the literature. Moreover, the influence of ASA on BP demonstrated here indicates the need to identify and control for ASA effects in patients using ASA before and during their participation in antihypertension medication trials.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360028     DOI: 10.3109/07420529709001452

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  6 in total

Review 1.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Time-Dependent Hypotensive Effect of Aspirin in Mice.

Authors:  Lihong Chen; Guangrui Yang; Jiayang Zhang; Baoyin Ren; Soonyew Tang; Xuanwen Li; Garret A FitzGerald
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-12       Impact factor: 8.311

Review 3.  Evening versus morning dosing regimen drug therapy for hypertension.

Authors:  Ping Zhao; Ping Xu; Chaomin Wan; Zhengrong Wang
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

Review 4.  Antiplatelet agents and anticoagulants for hypertension.

Authors:  Gregory Yh Lip; Dirk C Felmeden; Girish Dwivedi
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

Review 5.  Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis.

Authors:  Nicholas Schwier; Nicole Tran
Journal:  Pharmaceuticals (Basel)       Date:  2016-03-23

Review 6.  Interactions between the Cyclooxygenase Metabolic Pathway and the Renin-Angiotensin-Aldosterone Systems: Their Effect on Cardiovascular Risk, from Theory to the Clinical Practice.

Authors:  Jakub Gawrys; Karolina Gawrys; Ewa Szahidewicz-Krupska; Arkadiusz Derkacz; Jakub Mochol; Adrian Doroszko
Journal:  Biomed Res Int       Date:  2018-10-02       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.